Publications

Detailed Information

Single-Molecule FRET based Screening Methodology for Topoisomerase-Targeting Drugs

DC Field Value Language
dc.contributor.advisor홍성철-
dc.contributor.authorKang Heo-
dc.date.accessioned2017-07-19T09:13:32Z-
dc.date.available2017-07-19T09:13:32Z-
dc.date.issued2012-08-
dc.identifier.other000000005509-
dc.identifier.urihttps://hdl.handle.net/10371/131659-
dc.description학위논문 (석사)-- 서울대학교 대학원 : 물리학과, 2012. 8. 홍성철.-
dc.description.abstractType II topoisomerases are an important target of anti-cancer and antibacterial drug development, but exact mechanisms of many type II topoisomerase-targeting drugs are not understood well. A fast and accurate way to understand how drug candidates interact with type II topoisomerases is required for efficient drug screening and drug development. In this work, we demonstrated that the unique capability of single-molecule FRET technique to monitor all the key reaction intermediates of the cleavage reaction of type II topoisomerases can be utilized for the screening of the three representative types of drugs: etoposide which inhibit the ligation step, ICRF 187 and I93 which trap the enzyme in the N-gate clamped conformation, and PCA which hinders the binding step of the enzyme. Detailed kinetic analysis further revealed that etoposide binding occurs after the cleavage reaction, and N-gate clamping of the enzyme by ICRF187/193 requires the enzyme-DNA interaction. We expect single-molecule FRET methodology will be a useful screening tool for type II topoisomerase-targeting drugs-
dc.description.tableofcontentsTable of Contents

1. Introduction………………………………………………………………..1
2. Materials and Methods
2.1. Protein purification………………………………..……………....3
2.2. Drug preparation…..………………………………………………3
2.3. DNA preparation……………………………………….……….….3
2.4. Single-molecule FRET experiment……………………………….4
2.5. Determination of kinetic rates………………………………….…6

3. Results and Discussions
3.1. Basic Mechanism of Type II Human Topoisomerase (hTopIIα) ………………………………………………………………….…..….7
3.2. When and how does the Etoposide works………………….……..8
3.3. Protocatechuic acid (PCA) inhibit the binding step during the catalytic cycle…………………………………….………………...…14
3.4. N-gate clamping of the enzyme by ICRF-187/193 requires the enzyme-DNA interaction……………..……………………………….16
4. Conclusion and Outlook………………………………………...………...22

References…………………………………………………………………...24
-
dc.formatapplication/pdf-
dc.format.extent1396496 bytes-
dc.format.mediumapplication/pdf-
dc.language.isoen-
dc.publisher서울대학교 대학원-
dc.subjectsmFRET-
dc.titleSingle-Molecule FRET based Screening Methodology for Topoisomerase-Targeting Drugs-
dc.typeThesis-
dc.description.degreeMaster-
dc.citation.pages31-
dc.contributor.affiliation자연과학대학 물리학과-
dc.date.awarded2012-08-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share